This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics To Present Five Clinical Studies At 2014 ASCO GU Cancer Symposium

SALT LAKE CITY, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from four studies in prostate cancer with Prolaris ® and one study in renal cancer will be presented at the 2014 ASCO Genitourinary Cancers Symposium, which will be held Jan. 30-Feb. 1, 2014 in San Francisco, Calif. Prolaris is a prognostic test that accurately predicts cancer-specific death and metastases based on an analysis of 46 cell cycle progression genes. The Prolaris score is a stronger predictor of prostate cancer death and recurrence than clinical parameters such as Gleason score and PSA and has been validated in 11 clinical studies with more than 5,000 patients. The Company also will present data from a study with an investigational prognostic test in development for renal cell carcinoma. 
Title:  Prolaris CCP score stratifies risk for prostate cancer patients at biopsy: initial commercial results.
Presenter:  David Crawford
Date:  Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST (Poster Session A)
Title:  Cell cycle progression score significantly modifies treatment decisions in prostate cancer: Results of an ongoing registry trial.
Presenter:  Ashok Kar
Date:  Friday, Jan. 31, 12:00 to 1:30 p.m. and 5:45 to 7:15 p.m. PST ( Poster Session B)
Title:  Prognostic utility of the cell cycle progression score generated from needle biopsy in men treated with prostatectomy.
Presenter:  Jay Bishoff
Date:  Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST (Poster Session A)
Title:  Cell cycle progression score to predict metastatic progression of clear cell renal carcinoma after resection.
Presenter:  Erik Askeland
Date:  Saturday, Feb. 1, 6:45 to 7:55 a.m. and 11:30 a.m. to 12:30 p.m. PST ( Poster Session C)

About Prolaris ®

Prolaris is a novel prognostic test developed by Myriad Genetics that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of multiple genes related to the progression of tumor cell division. Prolaris can identify low-risk patients who may be candidates for surveillance as well as patients who may be potentially at higher risk and would benefit from closer monitoring or additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in five published clinical trials. For more information visit: and .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: .

Myriad, the Myriad logo and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,826.59 +14.40 0.08%
S&P 500 2,091.71 +2.57 0.12%
NASDAQ 5,122.3180 +19.51 0.38%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs